FAQ

gp100:209-217(210M) peptide vaccine

Known as: G9 209-2M, gp100:209-217(210M) 
A synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2010
02419992010

Related topics

Related topics

6 relations
Antigen SensitizationCytotoxic T-LymphocytesMelanoma CellT-Cell Activation
(More)

Related mentions per year

Related mentions per year

1965-2018
1960198020002020
gp100:209-217(210M) peptide vaccine
Cytotoxic T-Lymphocytes
T-Cell Activation
immunopotentiation
gp100 Antigen
Antigen Sensitization

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
BACKGROUND Stimulating an immune response against cancer with the use of vaccines remains a challenge. We hypothesized that… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
2010
2010
Palliative care--a shifting paradigm.
n engl j med 363;8 nejm.org august 19, 2010 781 Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates 4. with tumor… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.
PURPOSE To identify prognostic factors associated with survival beyond 4 years and overall response in patients with metastatic… (More)
  • table 1
  • table 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2006
2006
Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.
Efforts to develop effective cancer vaccines often use combinations of immunogenic peptides to increase the applicability and… (More)
Is this relevant?
2004
2004
Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination.
Successful immunotherapy with peptide vaccines depends on the in vivo generation of sufficient numbers of anti-tumor T cells with… (More)
Is this relevant?
2003
2003
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
PURPOSE The purpose of this study was to evaluate the immunological responses and therapeutic effectiveness of immunization with… (More)
Is this relevant?
2002
2002
Functional heterogeneity of vaccine-induced CD8(+) T cells.
The functional status of circulating vaccine-induced, tumor-specific T cells has been questioned to explain their paradoxical… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Status of activation of circulating vaccine-elicited CD8+ T cells.
Selective blunting of the status of activation of circulating tumor-specific T cells was invoked to explain their paradoxical… (More)
  • table I
  • table II
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
2000
2000
A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12.
Twenty separate tumor infiltrating lymphocyte (TIL) bulk cultures and a tumor cell line were originated simultaneously from a… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression.
Although in vitro sensitization assays have shown increased melanoma Ag (MA)-specific CTL reactivity after vaccination with MA… (More)
  • figure 1
  • figure 2
  • table I
  • figure 3
  • figure 5
Is this relevant?